Mesenchymal Stem Cells Market Trends

  • Report ID: 3933
  • Published Date: Sep 09, 2025
  • Report Format: PDF, PPT

Mesenchymal Stem Cells Market Growth Drivers and Challenges:

Growth Drivers

  • Growing Prevalence of Genetic Diseases and Disorders – stem cells are used to repair tissues that are affected or damaged by the genetic mutation. Adult stem cells are highly utilized to cure genetic diseases and disorders. Common types of genetic diseases are Huntington’s, Cystic Fibrosis & Liver disease, and Sickle disease while types of genetic disorders are down syndrome, turner syndrome, Klinefelter syndrome, and others. The higher prevalence of these diseases is expected to hike the market growth over the forecast period. For instance, it was observed that in every 10 people, 6 of them suffer from a condition with genetic background.

  • Rising Geriatric Population – Elderly population is more prone to get diseases and disorders and the boom in elderly populations worldwide is anticipated to drive market growth during the forecast period. More than 60% of people across the globe will double from 12 to 22% between 2015 and 2050. Meanwhile, as of 2020, there were more people over the age of 60, and it is further expected that approximately 80% of the global geriatric population will dwell in low- and middle-income countries.

  • Increasing Instances of Cardiovascular Diseases – stem cell therapy is not helpful for all patients of cardiovascular disease but with lifestyle modification, it can be quite a safe and effective alternative treatment. Additionally, stem cells are noticed to be a non-surgical medium to repair damaged heart muscle. For instance, approximately 350,000 people lost their lives on account of coronary heart disease in 2020 across the globe.

  • Growing Cases of Parkinson’s Disease – it has been observed that mesenchymal stem cell therapy can repair the damaged brain cells by Parkinson’s disease but there is no medical proof that it can completely cure the disease. These cells are used to treat motor symptoms of Parkinson’s disease. For instance, it was estimated that around 88,000 new cases of Parkinson’s disease are diagnosed in the United States every year.

  • Rising Demand for Stem Cell Treatment in Type 1 Diabetesthere are several documented cases of type 1 diabetes where patients lived for years without needing insulin injections when using cord blood stem cells. For instance, approximately 8 million people across the globe were anticipated to have type 1 diabetes in 2021.

Challenges

  • Higher Cost Associated with Stem Cell Treatment
    Stem cell treatment is very expensive owing to several factors such as type of stem cell treatment, pre-treatment investigations, number of stem cells required, hospital stay, and others. The average cost of stem cell therapy is projected to reach approximately 30,000 U.S. dollars. This cost is observed to vary based on the transplant kind such as autologous and allogenic transplant.
  • Possibility of Administration Site Reaction and Tumor Growth
  • Formation of Inappropriate Cell type

Base Year

2025

Forecast Period

2026-2035

CAGR

13.3%

Base Year Market Size (2025)

USD 3.87 billion

Forecast Year Market Size (2035)

USD 13.49 billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of mesenchymal stem cells is estimated at USD 4.33 billion.

The global mesenchymal stem cells market size was more than USD 3.87 billion in 2025 and is anticipated to grow at a CAGR of over 13.3%, reaching USD 13.49 billion revenue by 2035.

Asia Pacific mesenchymal stem cells market secures the largest share by 2035, driven by increasing healthcare awareness and rising prevalence of cancer and cardiovascular diseases.

Key players in the market include Bio-Techne Corporation, Merck KGaA, Genlantis, Inc., Celprogen Corporation, PromoCell GmbH, Cyagen US Inc., Plus Therapeutics, Inc., Human Longevity, Inc., Thermo Fisher Scientific Inc., Pluristem Therapeutics Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos